Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases

Abstract Significant progress has been made in understanding the pre-symptomatic phase of amyotrophic lateral sclerosis. While much is still unknown, advances in other neurodegenerative diseases offer valuable insights. Indeed, it is increasingly clear that the well-recognized clinical syndromes of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, spinal muscular atrophy and frontotemporal dementia are also each preceded by a pre-symptomatic or prodromal period of varying duration, during which the underlying disease process unfolds, with associated compensatory changes and loss of inherent system redundancy. Key insights from these diseases highlight opportunities for discovery in amyotrophic lateral sclerosis. The development of biomarkers reflecting amyloid and tau has led to a shift in defining Alzheimer’s disease based on inferred underlying histopathology. Parkinson’s disease is unique among neurodegenerative diseases in the number and diversity of non-genetic biomarkers of pre-symptomatic disease, most notably REM sleep behaviour disorder. Huntington’s disease benefits from an ability to predict the likely timing of clinically manifest disease based on age and CAG-repeat length alongside reliable neuroimaging markers of atrophy. Spinal muscular atrophy clinical trials have highlighted the transformational value of early therapeutic intervention, and studies in frontotemporal dementia illustrate the differential role of biomarkers based on genotype. Similar advances in amyotrophic lateral sclerosis would transform our understanding of key events in pathogenesis, thereby dramatically accelerating progress towards disease prevention. Deciphering the biology of pre-symptomatic amyotrophic lateral sclerosis relies on a clear conceptual framework for defining the earliest stages of disease. Clinically manifest amyotrophic lateral sclerosis may emerge abruptly, especially among those who harbour genetic mutations associated with rapidly progressive amyotrophic lateral sclerosis. However, the disease may also evolve more gradually, revealing a prodromal period of mild motor impairment preceding phenoconversion to clinically manifest disease. Similarly, cognitive and behavioural impairment, when present, may emerge gradually, evolving through a prodromal period of mild cognitive impairment or mild behavioural impairment before progression to amyotrophic lateral sclerosis. Biomarkers are critically important to studying pre-symptomatic amyotrophic lateral sclerosis and essential to efforts to intervene therapeutically before clinically manifest disease emerges. The use of non-genetic biomarkers, however, presents challenges related to counselling, informed consent, communication of results and limited protections afforded by existing legislation. Experiences from pre-symptomatic genetic testing and counselling, and the legal protections against discrimination based on genetic data, may serve as a guide. Building on what we have learned—more broadly from other pre-symptomatic neurodegenerative diseases and specifically from amyotrophic lateral sclerosis gene mutation carriers—we present a road map to early intervention, and perhaps even disease prevention, for all forms of amyotrophic lateral sclerosis.

[1]  R. Petersen Aducanumab: What about the Patient? , 2021, Annals of neurology.

[2]  G. Rabinovici Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab. , 2021, The New England journal of medicine.

[3]  B. Dunn,et al.  Approval of Aducanumab for Alzheimer Disease-the FDA's Perspective. , 2021, JAMA internal medicine.

[4]  R. Finkel,et al.  Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial , 2021, The Lancet Neurology.

[5]  M. Mintun,et al.  Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.

[6]  J. V. van Swieten,et al.  Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[7]  D. Alexander,et al.  Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington’s disease , 2020, Science Translational Medicine.

[8]  P. Svenningsson,et al.  Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease , 2020, Movement disorders : official journal of the Movement Disorder Society.

[9]  A. Ludolph,et al.  Cerebrospinal Fluid Levels of Prodynorphin‐Derived Peptides are Decreased in Huntington's Disease , 2020, Movement disorders : official journal of the Movement Disorder Society.

[10]  Timothy A. Miller,et al.  Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. , 2020, The New England journal of medicine.

[11]  B. Boeve,et al.  Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies. , 2020, Annals of neurology.

[12]  D. Burke,et al.  A proposal for new diagnostic criteria for ALS , 2020, Clinical Neurophysiology.

[13]  G. Frisoni,et al.  Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers , 2020, Annals of neurology.

[14]  Joey Tianyi Zhou,et al.  A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG) , 2020, Orphanet Journal of Rare Diseases.

[15]  Michael Wagner,et al.  The characterisation of subjective cognitive decline , 2020, The Lancet Neurology.

[16]  B. Boeve,et al.  Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[17]  David T. Jones,et al.  Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study , 2019, Neurobiology of Aging.

[18]  Nick C Fox,et al.  Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study , 2019, The Lancet Neurology.

[19]  Nick C Fox,et al.  Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study , 2019, The Lancet Neurology.

[20]  David T. Jones,et al.  Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration , 2019, Alzheimer's & Dementia.

[21]  D. Berg,et al.  Parkinson disease genetics: too early to predict progression? , 2019, Nature Reviews Neurology.

[22]  David T. Jones,et al.  The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology , 2019, Alzheimer's & Dementia.

[23]  L. Servais,et al.  Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives , 2019, Therapeutics and clinical risk management.

[24]  J. Mendell,et al.  P.214Presymptomatic spinal muscular atrophy: reality or myth? , 2019, Neuromuscular Disorders.

[25]  Sebastian Heinzel,et al.  Update of the MDS research criteria for prodromal Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[26]  R. Finkel,et al.  Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study , 2019, Neuromuscular Disorders.

[27]  R. Reilmann,et al.  Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories , 2019, Movement disorders clinical practice.

[28]  P. Andersen,et al.  Neurofilaments in pre-symptomatic ALS and the impact of genotype , 2019, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[29]  David T. Jones,et al.  Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers , 2019, Neurobiology of Aging.

[30]  R. Petersen,et al.  Data from: Subjective cognitive decline and risk of MCI: the Mayo Clinic Study of Aging , 2019 .

[31]  W. M. van der Flier,et al.  Added value of amyloid PET in individualized risk predictions for MCI patients , 2019, Alzheimer's & dementia.

[32]  S. Fereshtehnejad,et al.  Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study. , 2019, Brain : a journal of neurology.

[33]  David T. Jones,et al.  Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers , 2019, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[34]  R. Barker,et al.  Targeting Huntingtin Expression in Patients with Huntington's Disease. , 2019, The New England journal of medicine.

[35]  Daniela Berg,et al.  Prodromal Parkinson's Disease: The Decade Past, the Decade to Come , 2019, Movement disorders : official journal of the Movement Disorder Society.

[36]  R. Finkel,et al.  Neurofilament as a potential biomarker for spinal muscular atrophy , 2019, Annals of clinical and translational neurology.

[37]  M. Benatar,et al.  Defining pre-symptomatic amyotrophic lateral sclerosis , 2019, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[38]  M. Ikram,et al.  The incidence of mild cognitive impairment: A systematic review and data synthesis , 2019, Alzheimer's & Dementia.

[39]  Veronica Redaelli,et al.  Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study , 2019, Brain : a journal of neurology.

[40]  Yves Dauvilliers,et al.  Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study , 2019, Brain : a journal of neurology.

[41]  B. Miller,et al.  Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials , 2019, Brain : a journal of neurology.

[42]  W. Jagust,et al.  18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes , 2019, Alzheimer's Research & Therapy.

[43]  Nick C Fox,et al.  Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease , 2019, Nature Medicine.

[44]  David T. Jones,et al.  Rates of lobar atrophy in asymptomatic MAPT mutation carriers , 2019, Alzheimer's & Dementia.

[45]  D. Alexander,et al.  Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease , 2018, Science Translational Medicine.

[46]  R. Petersen How early can we diagnose Alzheimer disease (and is it sufficient)? , 2018, Neurology.

[47]  Jung-Han Kim,et al.  Stereotactic Core-Needle Biopsy of Non-Mass Calcifications: Outcome and Accuracy at Long-Term Follow-Up , 2003, Korean journal of radiology.

[48]  Phil Woodward,et al.  Minimizing Patient Burden Through the Use of Historical Subject-Level Data in Innovative Confirmatory Clinical Trials: Review of Methods and Opportunities , 2018, Therapeutic innovation & regulatory science.

[49]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[50]  David T. Jones,et al.  In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms , 2018, Neurology.

[51]  R. Finkel,et al.  Nusinersen versus Sham Control in Later‐Onset Spinal Muscular Atrophy , 2018, The New England journal of medicine.

[52]  Ronald C. Petersen,et al.  Practice guideline update summary: Mild cognitive impairment , 2018, Neurology.

[53]  A. Al-Chalabi,et al.  ECAS A-B-C: alternate forms of the Edinburgh Cognitive and Behavioural ALS Screen , 2018, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[54]  Hiroko H. Dodge,et al.  Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set (UDS) , 2017, Alzheimer disease and associated disorders.

[55]  R. J. Ramamurthi,et al.  Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[56]  Brian K. Kaspar,et al.  Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[57]  K. Blennow,et al.  Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis , 2017, The Lancet Neurology.

[58]  D. Jennings,et al.  Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter–Deficit Prodromal Cohort , 2017, JAMA neurology.

[59]  C. Smart,et al.  Subjective Cognitive Decline in Preclinical Alzheimer's Disease. , 2017, Annual review of clinical psychology.

[60]  K. Blennow,et al.  Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease? , 2017, PloS one.

[61]  R. Freeman,et al.  Natural history of pure autonomic failure: A United States prospective cohort , 2017, Annals of neurology.

[62]  T. Hortobágyi,et al.  Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[63]  O. Hardiman,et al.  Identifying behavioural changes in ALS: Validation of the Beaumont Behavioural Inventory (BBI) , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[64]  Chengjie Xiong,et al.  The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model , 2017, Alzheimer's & Dementia.

[65]  Knut Engedal,et al.  Frontotemporal Dementia , 2016, Journal of geriatric psychiatry and neurology.

[66]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[67]  P. Andersen,et al.  Presymptomatic ALS genetic counseling and testing , 2016, Neurology.

[68]  C. Broeckhoven,et al.  Molecular genetics of early-onset Alzheimer's disease revisited , 2016, Alzheimer's & Dementia.

[69]  Eric E. Smith,et al.  Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment , 2016, Alzheimer's & Dementia.

[70]  Günther Deuschl,et al.  MDS research criteria for prodromal Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[71]  Lee Ashendorf,et al.  Reliable Change on Neuropsychological Tests in the Uniform Data Set , 2015, Journal of the International Neuropsychological Society.

[72]  Jane S. Paulsen,et al.  Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease , 2015, Cell.

[73]  M. Hayden,et al.  Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression , 2015, Scientific Reports.

[74]  S. Tabrizi,et al.  Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. , 2015, The Journal of clinical investigation.

[75]  S. Chandran,et al.  Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): A cognitive tool for motor disorders , 2015, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[76]  Veronica Redaelli,et al.  Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis , 2015, The Lancet Neurology.

[77]  Jane S. Paulsen,et al.  Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study , 2014, The Lancet Neurology.

[78]  N. Jetté,et al.  The prevalence of Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[79]  Andrew J. Saykin,et al.  A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease , 2014, Alzheimer's & Dementia.

[80]  E. Aylward Magnetic resonance imaging striatal volumes: A biomarker for clinical trials in Huntington's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[81]  Keith A. Johnson,et al.  Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants , 2014, Alzheimer's Research & Therapy.

[82]  Jane S. Paulsen,et al.  Huntington disease: natural history, biomarkers and prospects for therapeutics , 2014, Nature Reviews Neurology.

[83]  J. Karlawish,et al.  The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.

[84]  G. Deuschl,et al.  Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[85]  Elaine Niven,et al.  Screening for cognition and behaviour changes in ALS , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[86]  Chris Frost,et al.  Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data , 2013, The Lancet Neurology.

[87]  R. Finkel Electrophysiological and motor function scale association in a pre-symptomatic infant with spinal muscular atrophy type I , 2013, Neuromuscular Disorders.

[88]  W. Poewe,et al.  The PRIPS study: screening battery for subjects at risk for Parkinson's disease , 2013, European journal of neurology.

[89]  B. Berkman,et al.  When Does an Illness Begin: Genetic Discrimination and Disease Manifestation , 2012, The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.

[90]  I. Mackenzie,et al.  Advances in understanding the molecular basis of frontotemporal dementia , 2012, Nature Reviews Neurology.

[91]  Christopher A. Ross,et al.  Striatal Volume Contributes to the Prediction of Onset of Huntington Disease in Incident Cases , 2012, Biological Psychiatry.

[92]  K. Duff Evidence-based indicators of neuropsychological change in the individual patient: relevant concepts and methods. , 2012, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[93]  Jane S. Paulsen,et al.  Indexing disease progression at study entry with individuals at‐risk for Huntington disease , 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[94]  S. Bruley des Varannes,et al.  Parkinson disease , 2011, Neurology.

[95]  Ranjan Duara,et al.  Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. , 2011, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[96]  김태희,et al.  Wisconsin Card Sorting Test-64 Card Version(WCST-64)의 한국 노인 정상규준 연구 , 2011 .

[97]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[98]  H. Zetterberg,et al.  Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson’s disease , 2011, Acta neurologica Scandinavica.

[99]  T. Gollan,et al.  Self-ratings of spoken language dominance: A Multilingual Naming Test (MINT) and preliminary norms for young and aging Spanish–English bilinguals* , 2011, Bilingualism: Language and Cognition.

[100]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[101]  R. Petersen Clinical practice. Mild cognitive impairment. , 2011, The New England journal of medicine.

[102]  P. Andersen,et al.  Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis , 2011, Genetics in Medicine.

[103]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[104]  Chris Frost,et al.  Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis , 2011, The Lancet Neurology.

[105]  Bruce L. Miller,et al.  Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia , 2011, Neuropsychologia.

[106]  Jane S. Paulsen,et al.  CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[107]  R. D. de Haan,et al.  The cognitive profile of amyotrophic lateral sclerosis: A meta-analysis , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[108]  M. York,et al.  Detecting frontotemporal dysfunction in ALS: Utility of the ALS Cognitive Behavioral Screen (ALS-CBS™) , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[109]  寺田 達弘,et al.  Frontal Systems Behavior Scale (FrSBe) , 2009 .

[110]  Jane S. Paulsen,et al.  Motor abnormalities in premanifest persons with Huntington's disease: The PREDICT‐HD study , 2009, Movement disorders : official journal of the Movement Disorder Society.

[111]  Nick C Fox,et al.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data , 2009, The Lancet Neurology.

[112]  M. Freedman,et al.  Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[113]  Roger A. Barker,et al.  The Cambridge Behavioural Inventory revised , 2008, Dementia & neuropsychologia.

[114]  Jane S. Paulsen,et al.  Detection of Huntington’s disease decades before diagnosis: the Predict-HD study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[115]  M. Benatar,et al.  Diagnostic Accuracy of Thoracic Paraspinal Electromyography in Amyotrophic Lateral Sclerosis , 2007, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[116]  M. Benatar,et al.  The electromyographic diagnosis of amyotrophic lateral sclerosis: Does the evidence support the El Escorial criteria? , 2007, Muscle & nerve.

[117]  S. Tabrizi,et al.  Predict-HD and the future of therapeutic trials , 2006, The Lancet Neurology.

[118]  Jane S. Paulsen,et al.  Preparing for preventive clinical trials: the Predict-HD study. , 2006, Archives of neurology.

[119]  Mark B Bromberg,et al.  Natural history of denervation in SMA: Relation to age, SMN2 copy number, and function , 2005, Annals of neurology.

[120]  R. Petersen Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[121]  B. Miller,et al.  Are amyotrophic lateral sclerosis patients cognitively normal? , 2003, Neurology.

[122]  T. Wienker,et al.  Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. , 2002, American journal of human genetics.

[123]  Michael J. Taylor,et al.  Sensitivity and specificity of WAIS–III/WMS–III demographically corrected factor scores in neuropsychological assessment , 2001, Journal of the International Neuropsychological Society.

[124]  S. Baron-Cohen,et al.  The "Reading the Mind in the Eyes" Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. , 2001, Journal of child psychology and psychiatry, and allied disciplines.

[125]  E. Kaplan,et al.  The Boston naming test , 2001 .

[126]  L. Goldstein,et al.  Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS) , 2000, Neuropsychologia.

[127]  Arnold Munnich,et al.  Correlation between severity and SMN protein level in spinal muscular atrophy , 1997, Nature Genetics.

[128]  M. MacDonald,et al.  CAG repeat number governs the development rate of pathology in Huntington's disease , 1997, Annals of neurology.

[129]  A. Kertesz,et al.  Frontal Behavioral Inventory: Diagnostic Criteria for Frontal Lobe Dementi , 1997, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[130]  K. Zerres,et al.  Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. , 1995, Archives of neurology.

[131]  G. Chelune,et al.  'T scores for change': An illustration of a regression approach to depicting change in clinical neuropsychology , 1993 .

[132]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[133]  N. Jacobson,et al.  Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. , 1991, Journal of consulting and clinical psychology.

[134]  O. Spreen,et al.  Predicting premorbid IQ: A revision of the national adult reading test , 1989 .

[135]  Cecil R. Reynolds,et al.  A demographically based index of premorbid intelligence for the WAIS—R. , 1984 .

[136]  A. Benton,et al.  Visuospatial judgment. A clinical test. , 1978, Archives of neurology.

[137]  S J Pocock,et al.  The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.

[138]  Jane S. Paulsen,et al.  Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. , 2016, JAMA neurology.

[139]  Fang Chen,et al.  Use of historical control data for assessing treatment effects in clinical trials , 2014, Pharmaceutical statistics.

[140]  T. Schneid,et al.  The Genetic Information Nondiscrimination Act of 2008 (GINA) , 2011 .

[141]  N. Talley Medical records documentation of constipation preceding Parkinson disease: A case-control study , 2010 .

[142]  S. Hersch At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. , 2006, Archives of neurology.

[143]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.